Morgan Stanley
ROIV icon

Morgan Stanley’s Roivant Sciences ROIV Stock Holding History

Morgan Stanley’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51B Sell
42,592,905
-9,235,420
-18% -$273M 0.08% 219
2026
Q1 		$1.44B Sell
51,828,325
-6,531,228
-11% -$168M 0.09% 206
2025
Q4 		$1.27B Buy
58,359,553
+14,036,696
+32% +$277M 0.08% 231
2025
Q3 		$671M Sell
44,322,857
-371,109
-0.8% -$4.59M 0.04% 428
2025
Q2 		$504M Buy
44,693,966
+8,767,207
+24% +$95M 0.03% 495
2025
Q1 		$363M Buy
35,926,759
+1,311,686
+4% +$14.2M 0.03% 584
2024
Q4 		$409M Buy
34,615,073
+4,941,069
+17% +$58.4M 0.03% 543
2024
Q3 		$342M Buy
29,674,004
+343,865
+1% +$3.91M 0.02% 603
2024
Q2 		$310M Sell
29,330,139
-6,305,362
-18% -$69.1M 0.02% 616
2024
Q1 		$376M Buy
35,635,501
+13,708,457
+63% +$148M 0.03% 547
2023
Q4 		$246M Buy
21,927,044
+2,615,413
+14% +$25.5M 0.02% 686
2023
Q3 		$226M Buy
19,311,631
+6,324,915
+49% +$71.5M 0.02% 646
2023
Q2 		$131M Buy
12,986,716
+9,810,452
+309% +$87.8M 0.01% 928
2023
Q1 		$23.4M Buy
3,176,264
+2,831,760
+822% +$23.3M ﹤0.01% 2249
2022
Q4 		$2.75M Buy
344,504
+303,340
+737% +$1.69M ﹤0.01% 4244
2022
Q3 		$132K Buy
41,164
+14,982
+57% +$58K ﹤0.01% 5936
2022
Q2 		$106K Buy
26,182
+25,869
+8,265% +$103K ﹤0.01% 6243
2022
Q1 		$2K Sell
313
-427
-58% -$2.82K ﹤0.01% 7755
2021
Q4 		$7K Buy
+740
New +$6.16K ﹤0.01% 7575

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's ROIV Position: Q2 2026 in Review

Morgan Stanley reduced its Roivant Sciences (ROIV) stake by 18% in Q2 2026, selling an estimated $273M and leaving 42,592,905 shares worth $1.51B. The position accounts for 0.08% of the portfolio, ranked #219.

Morgan Stanley first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. 497 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Morgan Stanley held 42,592,905 shares of Roivant Sciences worth $1.51B as of Q2 2026.
  • Morgan Stanley sold 9,235,420 Roivant Sciences shares in Q2 2026, an estimated $273M.
  • Roivant Sciences made up 0.08% of Morgan Stanley's portfolio in Q2 2026, its #219 holding.
  • Morgan Stanley first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
  • 497 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.